Explore a proposed consensus definition of severe COPD and a structured work-up addressing symptoms, functional impairment, quality of life and clinical characteristics.
GOLD and GLI provide a joint position on spirometry for diagnosing COPD, supporting the fixed FEV1/FVC ratio in the appropriate clinical context.
Joint GOLD/GLI statement on spirometry to define airflow obstruction and confirm COPD diagnosis, aiming to harmonize criteria and improve global practice.
Whole-genome cfDNA profiling identifies molecular clusters and pathways associated with oxidative damage and airflow limitation in COPD patients.
Study exploring the association between eosinophils and circulating autoantibodies in COPD patients, considering airflow limitation and smoking status.
This study identifies a metabolic signature of COPD patients, involving fatty acids, amino acid and carbohydrate metabolites, using LC-MS plasma profiling.
Un estudio reciente en Osona (Cataluña) refleja que 20,7% de jóvenes presenta alteraciones espirométricas. También revela síntomas y factores de riesgo en la población joven ambulatoria.
Proteomic Predictors of Mortality in Stable COPD is the objective of this pilot study. It searchs to identify proteomic markers and specific multiprotein signatures that could be useful in predicting long-term mortality
Protocolised treatable trait-based asthma management was acceptable to patients not under the care of a severe asthma clinic, associated with significant clinical benefit, and a full trial appears feasible.
Siprometry to diagnose COPD: GOLD 2025 recommends using pre-BD spirometry to rule out COPD and post-BD to confirm, ensuring volume responders are not overlooked.
